uclm802
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2023 (NCT05775666)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- MesothelinImmunity, passive
MSLN immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05848999 | Phase 1 | Apr 27, 2023 | UTC Therapeutics Inc., Zhejiang University |
| NCT05775666 | Phase 1 | Mar 31, 2023 | Peking University, UTC Therapeutics Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UTC Therapeutics Inc. | For profit | 2 | 0 | 1 | 2023 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1